MESOTHELIOMA | 2025-12-23

ADI-PEG20 Breakthrough: New Mesothelioma Treatment Quadruples Three-Year Survival Rates

Groundbreaking Clinical Trial Results Bring Hope to California Mesothelioma Patients with Aggressive Subtypes

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

A revolutionary mesothelioma treatment called ADI-PEG20 (pegargiminase) has demonstrated remarkable results in a landmark international clinical trial, offering new hope to patients diagnosed with aggressive nonepithelioid mesothelioma subtypes. The ATOMIC-Meso trial, a Phase 2-3 double-blind randomized study conducted at 43 centers across five countries, found that patients receiving ADI-PEG20 combined with chemotherapy survived an average of 9.3 months compared to 7.7 months for those recei...

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301